ACCELERATING DEVELOPMENT AND
INCREASING AWARENESS AND ACCESS
OF PATIENTS WITH CANCER
TO IMMUNOTHERAPY

T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union’s Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T-cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.

Join T2EVOLVE at the 5th European CAR T-cell meeting

The 5th European CAR T-cell Meeting takes place in Rotterdam, the Netherlands, on February 9-11, 2023. The meeting is the largest CAR-T event in Europe in 2023. The previous edition of the meeting had more than 1.000 on-site participants and 120 abstracts. For the...

Hélène Negre and Michael Hudecek to speak at Onco Cell Therapy Summit Europe

Hélène Negre, T2EVOLVE Project Leader, and Michael Hudecek, T2EVOLVE Project Coordinator, are speakers at the Onco Cell Therapy Summit Europe in Amsterdam on Thursday, November 3. Hélène will present the T2EVOLVE Consortium while Michael speaks about new targets and...
Photo from the Strategic Consortium meeting in Paris

First face-to-face Strategic Consortium meeting takes place in Paris

The first face-to-face T2EVOLVE Strategic Consortium meeting took place in Paris over the course of two days last week. It was a pleasure for our work package team leads and contributors and T2EVOLVE coordinators to finally meet in person and work together. We hope to...

Spotlight sessions kick off

On September 19, the first T2E Spotlight Session kicked off with great success. Thanks to our speakers Juan Jose Lasarte (UNAV) and Maik Luu (UKW) for their insights into how to overcome the suppressive tumor microenvironment with new technologies and concepts and...

European School of Hematology Conference

Michael Hudecek of  T2EVOLVE  is chairing the upcoming European School of Hematology Conference in Berlin with Chiara Bonini  and Stan Riddell.

Coming soon: European patient survey on CAR T-cell therapy – Help us to gain insights into patients’ experiences, quality of life and unmet needs

After months of preparation and close collaboration with patient advocacy groups, patients and carers, we are proud to launch our European patient survey on CAR T-cell therapy! This survey will help us to understand patients’ experiences with CAR T-cell therapy,...

EHA2022 Congress

The EHA congress in Vienna is getting closer!  https://ehaweb.org/congress/eha2022-hybrid/eha2022-congress/ If you are joining the event please be sure to stop by the T2EVOLVE walk-in room  on Saturday 11th June 10:30am-12:30pm (Room Schubert 2) where we can meet and...

ICLE 2022 |31th March – 2st April Munich

Maik Luu will present T2EVOLVE at the ICLE in Munich (31th March- 2nd April).

European survey on patient experience of CAR-T cell therapy will be coming soon.

CAR T-cell therapy

Engineered T-cell therapy is a revolutionary cancer treatment where a patient’s immune cells are reprogrammed to seek and destroy cancer cells. This transformative treatment has the potential to cure cancer with a single shot. This therapy is approved and available in the EU for the treatment of leukemia and has the potential to become a blockbuster therapy for other types of cancer, as well as infectious diseases and autoimmune diseases in the future.

For additional information on CAR T-cell technology please contact UKW.

Leadership

Director CAR-T Research Program, Cellular Immunotherapy for Malignant Diseases Max Eder Research Group‚ CAR T-cell engineering, Universitätsklinikum Würzburg, Germany

Prof Michael Hudecek, MD

T2EVOLVE Project Coordinator

Scientific Director Bioproduction and Bioprocessing at Servier, and EFPIA project leader for T2EVOLVE IMI Consortium,
Suresnes Cedex, France 

Dr Hélène Negre, PhD

T2EVOLVE Project Leader

Funding

This project received funding from the innovative Medicines initiative 2 Joint Undertaking (JU) under grant agreement No 945393. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programe and EFPIA. More information can be found at: https://www.imi.europa.eu/

Share This